PROFILPELAJAR.COM

Dezandrodeg

Dezandrodeg
Clinical data
Other namesAR-LDD; BMS-986365; BMS986365; CC-0094676; CC0094676; CC-94676; CC94676; CEL-007452; CEL007452
Routes of
administration		Oral[1]
Drug classAntiandrogen; Androgen receptor antagonist; Androgen receptor degrader
Identifiers
  • 2-[(2R)-4-[2-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-ethylphenoxy]ethyl]-2-methylpiperazin-1-yl]-N-[3-[(2,6-dioxopiperidin-3-yl)amino]phenyl]acetamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC41H45F3N8O5S
Molar mass818.92 g·mol−1
3D model (JSmol)
  • CCC1=C(C=CC(=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)OCCN4CCN([C@@H](C4)C)CC(=O)NC5=CC=CC(=C5)NC6CCC(=O)NC6=O
  • InChI=1S/C41H45F3N8O5S/c1-5-26-19-31(52-39(58)51(38(56)40(52,3)4)30-10-9-27(22-45)32(21-30)41(42,43)44)11-13-34(26)57-18-17-49-15-16-50(25(2)23-49)24-36(54)47-29-8-6-7-28(20-29)46-33-12-14-35(53)48-37(33)55/h6-11,13,19-21,25,33,46H,5,12,14-18,23-24H2,1-4H3,(H,47,54)(H,48,53,55)/t25-,33?/m1/s1
  • Key:YUVGVJYLOFTILT-NHYGQJMQSA-N

Dezandrodeg (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names BMS-986365 and CC-94676) is an antiandrogen which is under development for the treatment of prostate cancer.[1][2][3][4] It is taken orally.[1] The drug acts as a dual androgen receptor antagonist and androgen receptor degrader.[1][2][3][4] It is under development by Celgene Corporation and Bristol-Myers Squibb.[1][2] As of June 2026, dezandrodeg is in phase 3 clinical trials for prostate cancer.[1][2] It was also under development for the treatment of solid tumors, but no recent development has been reported.[1]

See also

References

  1. ^ a b c d e f g "Celgene Corporation". AdisInsight. 15 June 2026. Retrieved 28 July 2026.
  2. ^ a b c d "Delving into the Latest Updates on Dezandrodeg with Synapse". Synapse. 3 July 2026. Retrieved 28 July 2026.
  3. ^ a b Nayak S, Norris JD, Ammirante M, Rychak E, Wardell SE, Liao D, et al. (January 2026). "Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer". Clinical Cancer Research. 32 (1): 224–241. doi:10.1158/1078-0432.CCR-25-0471. PMC 12770934. PMID 40788283.
  4. ^ a b Mortensen DS, Nayak S, Plantevin-Krenitsky V, Horn EJ, Meiring J, Reiss S, et al. (July 2026). "Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365". Journal of Medicinal Chemistry. 69 (14): 16346–16362. doi:10.1021/acs.jmedchem.6c01590. PMID 42430428.
Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.